Physician profile
Kylee Kus
NPI 1790425726
$3,510.39
in general payments reported to CMS, 2019-2025
21 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $248 · 2023: $627 · 2024: $1,505 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,015 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,015.00 |
| Education | $246.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $595.11 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $470.64 | 2022-2025 | Libtayo, Dupixent |
| Abbvie INC. | $463.45 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $352.88 | 2024-2025 | Zoryve |
| Ucb, INC. | $206.64 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $182.29 | 2022-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.89 | 2024 | Spevigo |
| Janssen Scientific Affairs, LLC | $134.59 | 2025 | Tremfya |
| Mimedx Group, INC. | $130.76 | 2024 | |
| Krystal Biotech INC | $124.99 | 2023 | Vyjuvek |
| Incyte Corporation | $116.64 | 2025 | Opzelura |
| Lnhc, INC | $102.40 | 2025 | Zelsuvmi |
| Sun Pharmaceutical Industries INC. | $86.68 | 2023-2025 | Ilumya |
| Amgen INC. | $77.72 | 2024-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $69.05 | 2023-2024 | |
| Pfizer INC. | $46.09 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $43.08 | 2023 | Valchlor |
| Novartis Pharmaceuticals Corporation | $37.44 | 2024-2025 | |
| Organon LLC | $31.05 | 2025 | Vtama |
| Biofrontera INC. | $21.00 | 2025 | Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kylee Kus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.